	US 11,951,182 B2
	Combination therapy for treatment of thoracic cancer using Ad-REIC/Dkk-3 and a checkpoint inhibitor
Hiromi Kumon, Okayama (JP); and Bryan Burt, Houston, TX (US)
Assigned to Momotaro-Gene Inc., Okayama (JP)
Appl. No. 17/290,656
Filed by Momotaro-Gene Inc., Okayama (JP)
PCT Filed Nov. 1, 2019, PCT No. PCT/JP2019/043151 § 371(c)(1), (2) Date Apr. 30, 2021, PCT Pub. No. WO2020/091066, PCT Pub. Date May 7, 2020.
Claims priority of provisional application 62/831,108, filed on Apr. 8, 2019.
Claims priority of provisional application 62/754,226, filed on Nov. 1, 2018.
Prior Publication US 2021/0402010 A1, Dec. 30, 2021
Int. Cl. A61K 48/00 (2006.01); A61K 38/17 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); C12N 15/86 (2006.01)

CPC A61K 48/0058 (2013.01) [A61K 38/1709 (2013.01); A61K 39/3955 (2013.01); A61K 48/0066 (2013.01); A61P 35/00 (2018.01); C12N 15/86 (2013.01); A61K 2039/505 (2013.01); C12N 2710/10043 (2013.01); C12N 2710/10071 (2013.01)]

6 Claims

1. A method for treating thoracic cancer which is resistant to anti-PD-1 or anti-PD-L1 antibody immunotherapy, comprising administering to a subject with thoracic cancer a combination consisting of an Ad-REIC/Dkk-3, a check point inhibitor, and a carrier, wherein the Ad-REIC/Dkk-3 is an adenovirus vector comprising:

(i) a CMV promoter;

(ii) the following REIC/Dkk-3 DNA:

(a) DNA comprising the nucleotide sequence shown in SEQ ID NO: 1, or

(b) DNA having at least 90% sequence identity with the nucleotide sequence shown in SEQ ID NO:1,

(iii) a polyA sequence; and

(iv) enhancers prepared by linking an human Telomerase Reverse Transcriptase (hTERT) enhancer, an SV40 enhancer, and a CMV enhancer, wherein the hTERT enhancer is 5′ of the SV40 enhancer, and the SV40 enhancer is 5′ of the CMV enhancer,

wherein the thoracic cancer is a mesothelioma or an EGFR-mutant lung cancer.